Comparing two different drug methods for infertility treatment by assisted reproduction techniques (ARTs)
Phase 2
- Conditions
- infertility.Female infertility
- Registration Number
- IRCT201205309910N1
- Lead Sponsor
- Isfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 136
Inclusion Criteria
undergoing assisted reproduction techniques (ARTs) for the first time, age =35years and serum FSH level =10 IU/liter. Exclusion criteria: women with the previous history of IVF or ICSI; patients who had hyperprolactinemia, thyroid dysfunction, uterine abnormality, severe endometriosis and secondary infertility.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ovarian hyperstimulation syndrome. Timepoint: 10 days after HCG injection and during primary Trimester. Method of measurement: as presence of enlarged ovarian cysts more than 12 by 12 cm, ascites, pleural and/or pericardial effusion, electrolyte imbalance ,hypovolemia, and hypovolemic shock.;Fertility. Timepoint: after primary Trimester. Method of measurement: ultrasonography.
- Secondary Outcome Measures
Name Time Method umber of retrieved oocytes. Timepoint: 2 weeks after intervention. Method of measurement: number of retrieved oocytes in retrieval day.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate GnRH agonist and antagonist protocols in preventing ovarian hyperstimulation syndrome?
How does the GnRH agonist protocol compare to standard-of-care treatments for female infertility in terms of clinical outcomes and safety profiles?
Which biomarkers are associated with successful ovarian response in GnRH antagonist versus agonist protocols for infertility treatment?
What are the potential adverse events and management strategies specific to GnRH agonist and antagonist protocols in ARTs?
Are there combination approaches or competitor drugs that enhance the efficacy of GnRH protocols in assisted reproduction techniques?